Concert Pharmaceuticals, Inc.

Concert Pharmaceuticals Announces Data Presentations at Neuroscience 2011

Concert Pharmaceuticals Announces Data Presentations at Neuroscience 2011

October 19, 2011

Lexington, MA – Concert Pharmaceuticals, Inc. today announced that two abstracts related to the company’s deuterium-containing GABAA modulators have been accepted for poster presentations at The Society for Neuroscience Annual Meeting, Neuroscience 2011, being held November 12-16, 2011 in Washington, DC. Full abstracts can be viewed online at http://www.sfn.org/am2011/.

The schedule and details for Concert’s poster presentations at Neuroscience 2011 are as follows:

Affinnova, Inc.

Computer Backup Company Uses Affinnova's Technology to Advance its Advertising Strategy

Computer Backup Company Uses Affinnova's Technology to Advance its Advertising Strategy

October 19, 2011

WALTHAM, Mass. -- Affinnova, Inc., the global leader in marketing innovation software and services, announced that Carbonite, Inc., a Boston-based provider of online computer backup and recovery services, has successfully used Affinnova's technology to identify a compelling advertising strategy that motivates consumers to buy.

Joule Unlimited, Inc.

Joule Wins Prestigious Wall Street Journal Technology Innovation Award

Joule Wins Prestigious Wall Street Journal Technology Innovation Award

October 18, 2011

Cambridge, Mass. – Joule today announced its recognition as the 2011 Wall Street Journal Technology Innovation Award Winner in the category of Energy, chosen for its transformational approach to highly-efficient renewable fuel production. In addition, Joule received the Silver award across all of the competition’s 16 categories, for which there were over 600 entrants from around the world.

Innovation Awards: Polymers put CO2 to use

Innovation Awards: Polymers put CO2 to use

October 17, 2011

Catalyst technology to capture and reuse carbon dioxide in polyols and polymers has won Novomer the award for Innovation with Best Environmental Benefit.

Waltham, Massachusetts, US-based sustainable polymer specialist Novomer has developed a technology platform that produces valuable, high-performance polymers from waste carbon dioxide. Novomer's process is based on an innovative catalyst system that uses CO2 as a primary raw material in the ­production of polypropylene and polyethylene carbonates that contain between 43 and 50% CO2 by weight.
 

Joule Unlimited Forges a Faster Path to Biofuels

Joule Unlimited Forges a Faster Path to Biofuels

October 16, 2011

Joule Unlimited Technologies Inc. won the Silver in this year's Wall Street Journal Technology Innovation Awards for developing a more efficient technique for producing biofuel.

The Cambridge, Mass.-based company has created genetically engineered micro-organisms that secrete ethanol, diesel fuel and other hydrocarbons from water, sunlight and carbon dioxide. The use of these patented organisms eliminates some of the costly processing steps needed to turn plants into motor fuel.

Click on WSJ logo to view full article

Quanterix Corporation

Quanterix PSA Test Found to be a Reliable Predictor of Prostate Cancer Recurrence Following Surgery

Quanterix PSA Test Found to be a Reliable Predictor of Prostate Cancer Recurrence Following Surgery

October 13, 2011

CAMBRIDGE, Mass. -- Quanterix Corporation, a company enabling a new generation of molecular diagnostic tests based on its revolutionary Single Molecule Array (SiMoA™) technology, today announced results from a clinical evaluation of its Prostate Specific Antigen (PSA) test, a fifth-generation digital immunoassay, demonstrating that the assay is a reliable predictor of five-year biochemical recurrence (BCR)-free survival following radical prostatectomy (RP).  The pilot study was published online by the British Journal of Urology International. 

Black Duck Software, Inc.

Black Duck Software Secures $12 Million in New Funding Round Led By Split Rock Partners

Black Duck Software Secures $12 Million in New Funding Round Led By Split Rock Partners

October 13, 2011

Waltham, Mass. -- Black Duck Software, the leader in open source software knowledge, adoption and governance, today announced it has closed a $12M round of financing led by new investor Split Rock Partners, with participation from its existing investors as well. The company, which has been cash-flow positive since 2009, will use the funds to accelerate growth, advance key development projects, continue acquisitions and expand its global presence

Avedro, Inc.

Avedro Appoints A. John Kanellopoulos, MD to Its Medical Advisory Board

Avedro Appoints A. John Kanellopoulos, MD to Its Medical Advisory Board

October 13, 2011

WALTHAM, Mass.-- Avedro, Inc., a privately held medical device and pharmaceutical company, today announced A. John Kanellopoulos, MD has been named to its Medical Advisory Board. Dr. Kanellopoulos is a Clinical Professor of Ophthalmology at the NYU School of Medicine and Director of the Laser Vision Institute, Athens, Greece.

Alvine Pharmaceuticals, Inc.

Alvine Pharmaceuticals Announces Positive Results From Phase 2a Trial of ALV003 in Celiac Disease Patients

Alvine Pharmaceuticals Announces Positive Results From Phase 2a Trial of ALV003 in Celiac Disease Patients

October 11, 2011

SAN CARLOS, CA -- Alvine Pharmaceuticals, Inc. today announced positive results from its Phase 2a clinical trial of ALV003, which demonstrated the ability of ALV003 to attenuate gluten-induced intestinal mucosal injury in serologically negative celiac disease patients maintained on a gluten-free diet for one or more years. The study findings will be presented in a late breaking oral session at the 19th United European Gastroenterology Week (UEGW) in Stockholm on October 24.

Agios Pharmaceuticals, Inc.

Celgene and Agios Extend Cancer Metabolism Collaboration

Celgene and Agios Extend Cancer Metabolism Collaboration

October 5, 2011

CAMBRIDGE, Mass., Oct 05, 2011 -- Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the rapidly emerging field of cancer metabolism, today announced that Celgene Corporation (NASDAQ: CELG) and Agios have agreed, ahead of schedule, to extend the initial period of exclusivity of the companies' April 2010 collaboration agreement from three to four years. During this period, Celgene has an exclusive option to drug candidates generated by Agios' cancer metabolism research platform.